

# **Estimation Of Vitamin D Level And Its Effect On Bone Density In Systemic Sclerosis Patients**

Thesis

*Submitted in partial fulfillment of the  
Requirement of Master Degree in*

Rheumatology and Rehabilitation Medicine

By

**Sahar Saad Ibrahim**

(M.B.B.Ch) faculty of medicine

Cairo University

Under the supervision of

**Prof. Dr. Manal Mohamed Sedky**

*Prof. of Rheumatology and Rehabilitation*

*Faculty of Medicine*

*Cairo University*

**Prof. Dr. Lamiaa Ali Mansour**

*Prof. of Clinical and Chemical Pathology*

*Faculty of Medicine*

*Cairo University*

**Dr. Hend Helal Al-Sherbeni**

*Lecturer of Rheumatology and Rehabilitation*

*Faculty of Medicine*

*Cairo University*

Faculty of medicine

Cairo University

2011

بسم الله الرحمن الرحيم  
قالوا سبحانك لا علم لنا الا ما علمتنا انك انت العليم الحكيم  
صدق الله العظيم

(سورة البقرة ايه ٣٢)

## **Abstract**

**Objectives and Aim of the work:** The specific aim was to study the level of vitamin D in systemic sclerosis patients and to study its effect on bone density evaluated by DEXA.

**Patients and Methods:** 25 patients with systemic sclerosis and 25 healthy persons who served as control participated in this study. All patients and controls were subjected to full history taking, clinical examination, laboratory investigations (including serum 25 (OH) vitamin D) and radiological evaluation including DEXA.

**Results:** the frequency of vitamin D deficiency was highly statistically significant in systemic sclerosis patients (60%) when compared to controls (20%) (p value=0.018).

As regards the different positive DEXA findings, there was a highly significant difference between DEXA findings in SSc patients compared to controls (p value=0.000) (as it was found that 10/25 patients (40%) had osteoporosis, 9/25 patients (36%) had osteopenia and 6/25 patients (24%) had normal bone density while in controls there were only 2/25 persons (8%) who had osteopenia, the rest were normal.

**Conclusion:** systemic sclerosis patients had significantly higher vitamin D deficiency when compared to control. A highly significant difference was found concerning DEXA findings of systemic sclerosis patients when compared to control.

**Recommendations:** We recommend that vitamin D level in all patients with autoimmune diseases especially systemic sclerosis should be evaluated, vitamin D and calcium supplementation should be given to systemic sclerosis patients.

**Key words:**

- Systemic sclerosis      - Vitamin D      -DEXA

## **ACKNOWLEDGEMENT**

*I would like to start by thanking god for his help during this work as a little part of his generous help through out my life.*

*I wish to express my sincere gratitude to Prof.Dr. Manal Mohamed Sedky, professor of Rheumatology and Rehabilitation medicine, faculty of medicine, Cairo University for her great support during the study and for her privilege valuable supervision.*

*My great appreciation and sincere thanks for Prof. Dr. Lamiaa Ali Mansour Professor of clinical and chemical pathology, faculty of medicine, Cairo University for her continuous advice all through this work.*

*I am greatly indebted to Dr. Hend Helal Al- Sherbeni lecturer of Rheumatology and Rehabilitation, faculty of medicine, Cairo University who gave me much of her experience and support.*

*I wish also to thanks my professors and my colleges in Rheumatology and Rehabilitation department, faculty of medicine, Cairo University who support me in this work.*

*Finally I thank my family, my mother who stood beside me, gave me a lot of her time, and support and my sisters for their extreme kindness.*

## Contents

Item	Page
<b>Acknowledgement</b>	
<b>List of abbreviations</b>	I
<b>List of tables</b>	IV
<b>List of figures</b>	V
<b>Introduction and aim of the work</b>	1
<b>Review of literature</b>	
<b>Chapter I: vitamin D</b>	
• introduction	3
• forms	4
• evolutions	8
• production in the skin	8
• mechanism of action	10
• adequate intake	12
• natural sources	13
• artificial sources	14
• measuring vitamin D status	16
• deficiency	18
• overdose by ingestion	22
• health effect	26
- immune system	26
- influenza	27
- cancer	27
- cardiovascular disease	30
- mental health	32
- mortality	32
<b>Chapter II: vitamin D and autoimmune diseases</b>	
• introduction	34
• rheumatoid arthritis	36
• systemic lupus erythromatosis	41
• dermatomyositis	45
• undifferentiated connective tissue diseases	48
<b>Chapter III: vitamin D and systemic sclerosis</b>	
• systemic sclerosis	51

<ul style="list-style-type: none"> <li>• criteria <ul style="list-style-type: none"> <li>- major criteria</li> <li>- minor criteria</li> </ul> </li> <li>• classification <ul style="list-style-type: none"> <li>- limited cutaneous systemic sclerosis</li> <li>-diffuse cutaneous systemic sclerosis</li> </ul> </li> <li>• vitamin D and systemic sclerosis</li> </ul>	53 53 53 55 56 56 59
<b>Chapter VI: densitometry and osteoporosis</b>	
<ul style="list-style-type: none"> <li>• osteoporosis</li> <li>• limitation</li> <li>• candidates</li> <li>• types of tests</li> <li>• interpretation <ul style="list-style-type: none"> <li>- T score</li> <li>- Z score</li> </ul> </li> <li>• diagnosis of osteoporosis by using bone densitometry</li> <li>• how do we perform bone mass measurement?</li> <li>• the diagnosis of osteopenia and osteoporosis</li> <li>• how often should DEXA scans repeated to monitor treatment</li> <li>• the reasons are</li> </ul>	65 72 72 73 74 75 75 76  84 87 92  92
<b>Patients and methods</b>	96
<b>Results</b>	132
<b>Discussion</b>	155
<b>Summary and conclusion</b>	162
<b>Recommendations</b>	165
<b>References</b>	166
<b>Arabic summary</b>	194

## LIST OF ABBEVIATIONS

AI	Adequate intake
ACA	Anticentromere antibody
ACR	American College of Rheumatology
ALT	Alanine aminotransferase
ANA	Antinuclear antibody
AP	Anteroposterior
ARA	American Rheumatism Association
AST	Aspartate aminotransferase
ATA	Antitopiosomerase antibody
BMC	Bone mineral content
BMD	Bone mineral density
BMI	Body mass index
BUA	Broadband ultrasound attenuation
CI	Confidence interval
CK	Creatine kinase
Crest	Calcinosis, Raynaud's, esophagus dysmotility, sclerodacty and telangiectasia
CRP	C-reactive protein
CTD	Connective tissue disease
%CV	Percentage coefficient of variation
DAS	Disease activity score
DEXA	Dual energy X ray absorptiometry
DMARDs	Disease modifying antirheumatic drugs
DM	Dermatomyositis
DNA	Deoxyribonucleic acid
DPA	Dual photon absorptiometry
DSSc	Diffuse systemic sclerosis
DXR	Digital xray radiogrammetry
ELISA	Enzyme linked immunosorbent assay
ERT	Estrogen replacement therapy
ESR	Erythrocyte sedimentation rate
FDA	Food and Drug Administration
GIOP	Glucocorticoid induced osteoporosis
HAQ	Health assessment questionnaire score
HB	Haemoglobine

HCQ	Hydrochloroquine
HRT	Hormone replacement therapy
IBD	Inflammatory bowel disease
ICSSc	limited systemic sclerosis
IU	International unit
MCTD	Mixed connective tissue disease
µg	Microgram
MS	Multiple sclerosis
ng/ml	nanogram per millimeter
NFAT	Nuclear transcription factor AT
NF κB	Nuclear transcription factor kappa B
NHANES	National health and nutrition examination Survey
NSB	Non specific binding protein assay buffer
PABM	Peak adult bone mass
PAD	Peripheral artery disease
PLT	Platelets
PM	Polymyositis
QCT	Quantitative computed tomography
QUI	Quantitative ultrasound index
QUS	Qualitative ultrasound
RA	Rheumatoid arthritis
RNA	Ribonucleic acid
SD	Standard deviation
SERMs	Selective estrogen receptor modulators
SEXA	Single energy x ray absorptiometry
SI	Stiffness index
SIOP	Steroids induced osteoporosis
SLE	Systemic lupus erythematosus
SOS	Speed of sound
SPA	Single photon absorptiometry
SPAP	Systolic pulmonary artery pressure
SS	Systemic sclerosis
TLC	Total leucocytic count
TMB	Tetramethylbenzidine
TRP	Transient receptor potential
UCTD	Undifferentiated connective tissue disease



US	Ultrasound
UV	Ultraviolet
VDBP	Vitamin D binding protein
VDR	Vitamin D receptor
W	Width at the scanned line
WHO	World Health Organization
1,25 (OH) <sub>2</sub> D	1,25 dihydroxy vitamin D
25(OH)D	25 hydroxy vitamin D

## LIST OF FIGURES

Figure		Page
<b>Review of literature</b>		
Figure 1	The epidermal strata of the skin	9
Figure 2	The clinical spectrum of scleroderma	52
Figure 3	FTP measurement	110
Figure 4	Modified Rodnan skin thickness score	112
Figure 5	DEXA	127
Figure 6	Sex distribution in the study group	133
Figure 7	Showing the vitamin D concentration in patients and control group	141
Figure 8	showing vitamin D concentration and serum phosphorous in patients	147
Figure 9	Showing vitamin D concentration and telangiectasia in patients	148
Figure 10	Showing the relation of the presence of osteopenia and osteoporosis and age in patients	153
Figure 11	Showing the relation of the presence of osteopenia and osteoporosis and lung fibrosis in patients	154

## LIST OF TABLES

Table		Page
Review of literature		
Table 1	Forms of vitamin D	5
Table 2	SSc subsets according to LeRoy.et al 1988	57
Table 3	WHO criteria for the diagnosis of osteoporosis based on bone mass density	77
Table 4	Characteristics of central bone densitometry techniques	85
Table 5	Characteristics of peripheral bone densitometry techniques	86
Table 6	Patients with a normal peripheral bone density who may need additional bone mass testing	91
Table 7	Revised preliminary SSc severity scale	129
Table 8	Characteristics of patients and control group	133
Table 9	Characteristics of patients	134
Table 10	Patients` manifestations	135
Table 11	Severity skin score in patients	136
Table 12	Pulmonary function test in patients	136
Table 13	Steroids treatment of patients	137
Table 14	Basic laboratory findings in patients and control group	138
Table 15	Ca, ph, Alk ph in patients and controls	139
Table 16	The relation between Ca, Ph and Alk ph in patients and control group	139
Table 17	Vitamin D level in patients and controls	140
Table 18	Vitamin D concentration of patients and control group	140
Table 19	DEXA findings in patients compared to control	142
Table 20	Showing the difference of osteopenia, osteoporosis and osteopenia and osteoporosis together between patients and control group.	143
Table 21	DEXA in patients and control(T score	145

	and Z score)	
Table 22	Showing T score and Z score in patients and control group	145
Table 23	The relation between vitamin D concentration and different demographic, clinical and laboratory findings	146
Table 24	The relation between presence of oeteopenia and different demographic, clinical and laboratory findings	149
Table 25	The relation between presence of osteoporosis and different demographic, clinical and laboratory findings	150
Table 26	The relation between presence of osteopenia and osteoporosis and different demographic, clinical and laboratory findings	151

## **Introduction**

Vitamin D is a steroid hormone that regulates calcium metabolism and bone homeostasis (*Lips et al., 2006*).

It is widely recognized that vitamin D exerts important effects on many other systems, such as muscles, vasculature, reproduction, cellular growth and differentiation, malignancy, and the immune system. Vitamin D deficiency in adults can precipitate or exacerbate osteopenia and osteoporosis, cause osteomalacia and muscle weakness, and increase the risk of fracture (*Holick, 2007*).

Identification of vitamin D receptor (VDR) in most tissues and cells, including peripheral blood mononuclear cells was an important discovery (*Bhalla et al., 1983*).

The ability of several of these receptors to convert the primary circulating form, 25-hydroxy vitamin D, into the active form 1,25-dihydroxy vitamin D, has provided insights into the function of this vitamin ,particularly regarding its immunoregulatory effects. Vitamin D seems to be a physiological regulator of T cell development and VDR in Th(T helper) cells was identified (*Takeuchi et al., 1998*).

Epidemiological evidence indicates a significant association between vitamin D deficiency and an increased incidence of several autoimmune diseases like multiple sclerosis (MS), insulin dependent diabetes mellitus (IDDM), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) (*Kamen et al., 2006*).

On the other hand, increased vitamin D intake may have been associated with a decreased risk of IDDM, MS, and RA in the Iowa Women`s Health study (*Merlino et al., 2004*).

Low vitamin D levels have also been reported in patients with systemic sclerosis (*Orbach et al., 2007*). However no data are available on the relationship between a deficient vitamin D status and SSc disease activity and severity, nor on the clinical consequences that such deficiency might cause. Whether vitamin D could have a role in the complex pathogenesis of SSc remains unclear (*Allanore et al., 2008*).

### **Aim of the work**

This work is designed to study the level of vitamin D in systemic sclerosis patients and its effect on bone density by DEXA.

## **Vitamin D**

**Vitamin D** is a group of fat-soluble secosteroids, the two major physiologically relevant forms of which are vitamin D<sub>2</sub> (ergocalciferol) and vitamin D<sub>3</sub> (cholecalciferol). Vitamin D without a subscript refers to either D<sub>2</sub> or D<sub>3</sub> or both.

Vitamin D is produced in the skin of vertebrates after exposure to ultraviolet B light from the sun or artificial sources, and occurs naturally in a small range of foods. In some countries staples such as milk, flour and margarine are artificially fortified with vitamin D, and it is also available as a supplement in pill form (*Carlson and Costello, 1997*).

Vitamin D is carried in the bloodstream to the liver, where it is converted into the prohormone calcidiol. Circulating calcidiol may then be converted into calcitriol, the biologically active form of vitamin D, either in the kidneys or by monocyte-macrophages in the immune system. When synthesized by monocyte-macrophages, calcitriol acts locally as a cytokine, defending the body against microbial invaders (*Adams et al., 2010*).

When synthesized in the kidneys, calcitriol circulates as a hormone, regulating, among other things, the concentration of calcium and phosphate in the bloodstream, promoting the